JPRN-jRCT2080220749未知3 期
Phase 3 clinical study of AFT-801(confirmatory study 0305) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patients
Mitsubishi Tanabe Pharma Alfresa Pharma Corporation0 个研究点开始时间: 2009年6月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •Patients with a confirmed diagnosis of obstructive sleep apnea syndrome
- •Patients who have used a CPAP machine for at least three months and are able to continue its use during the study period
排除标准
- •Patients with existing narcolepsy, periodic limb movement disorder or central sleep apnea syndrome
- •Patients who work irregular hours or at night
- •Patients with chronic lack of sleep or irregular bedtime, etc.
研究者
相似试验
未知
3 期
Phase III clinical study of AFT-801 (confirmatory study) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsJPRN-jRCT2080220352Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
未知
3 期
Phase III clinical study of AFT-801 (long-term administration study) Open-label study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsJPRN-jRCT2080220353Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
未知
3 期
AJH801 Phase III Comparative Clinical Study in individuals with essential hypertensioHypertensionJPRN-jRCT2080221447Ajinomoto Pharmaceuticals Co., Ltd.600
已完成
3 期
Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugsAcute ischemic stroke (excluding cardioembolic stroke)JPRN-UMIN000000758Asahi Kasei Pharma Corporation770
招募中
3 期
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type IILeukocyte Adhesion DeficiencyNCT05462587AUG Therapeutics4